
CORRECTION**Chronic lymphocytic leukaemia**

Thomas J. Kipps, Freda K. Stevenson, Catherine J. Wu, Carlo M. Croce, Graham Packham, William G. Wierda, Susan O'Brien, John Gribben and Kanti Rai

Nature Reviews Disease Primers **3**, 16096 (2017)

In the version of the article originally published, a typographical error has now been corrected. The statement now reads: Approval of ibrutinib as initial therapy was based on the results of a randomized trial that showed a significant improvement in median PFS and overall survival in patients ≥ 65 years of age without del(17p) who were treated indefinitely with ibrutinib than in patients treated for up to 48 weeks with chlorambucil¹⁴⁶.